Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ara Katz has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The current prosecution activity is focused on this single technical domain. Practitioners should analyze the specific allowance rates and trends of this 1 distinct art unit to optimize their response strategy. The concentration of the portfolio suggests that the applicant is focusing intellectual property efforts on a specific biological or pharmaceutical innovation. This allows for a high degree of attention to the details of the pending matter.
The busiest examiner for the portfolio is TCHERKASSKAYA, OLGA V, who is currently managing 1 pending office action. This represents the total number of pending office actions for the portfolio. Having 1 distinct examiner and 1 distinct art unit means that the prosecution process is centralized. This allows for a targeted approach when addressing the requirements of the patent office. The workload of 1 busiest examiner pending 1 matter indicates a focus on a single active application. This streamlined prosecution environment reduces the complexity of managing multiple examiner interviews or conflicting art unit requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262870 | METHODS AND COMPOSITIONS FOR PRECISION RELEASE OF PROBIOTICS TO IMPROVE HUMAN HEALTH | TCHERKASSKAYA, OLGA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262870 | METHODS AND COMPOSITIONS FOR PRECISION RELEASE OF PROBIOTICS TO IMPROVE HUMAN HEALTH | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18262870 | METHODS AND COMPOSITIONS FOR PRECISION RELEASE OF PROBIOTICS TO IMPROVE HUMAN HEALTH | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Final Rejection | — | Pending | Jul 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAra Katz has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olga V Tcherkasskaya has the most, with 1 of Ara Katz's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
